DRs for Patient-Based Analysis
| Timing | 123I-MIBG SPECT/CT | 18F-DOPA PET/CT | P* |
| Before induction chemotherapy | |||
| Primary tumors | 15 (83%) | 17 (94%) | 0.5 |
| Soft-tissue metastases | 6 (50%) | 11 (92%) | 0.06 |
| Bone or bone-marrow metastases | 12 (92%) | 13 (100%) | 1.0 |
| After induction chemotherapy | |||
| Primary tumor | 13 (72%) | 15 (83%) | 0.6 |
| Soft-tissue metastases | 4 (33%) | 9 (75%) | 0.06 |
| Bone or bone-marrow metastases | 5 (38%) | 7 (54%) | 1.0 |
↵* Exact McNemar significance probability.
DRs (%) were calculated for each single diagnostic modality at each site of disease. Denominator for DRs on primary tumors is total number of patients (n = 18), considering that all are subjects with established cancer. For evaluations on soft-tissue and bone or bone-marrow lesions, denominator is maximum number of patients found to be positive by 2 diagnostic modalities (n = 12 for soft tissue; n = 13 for bone or bone-marrow lesions).